The Division of Hematology & Hematologic Malignancies works with each of these programs:
Benign Hematology Program
The Huntsman Cancer Institute at the University of Utah (HCI) is a wellspring of expertise for patients with benign hematologic disorders living in the Mountain West, the largest geographic catchment area in the United States. Our mission is to deliver coordinated, multispecialty care, as a medical home, for patients with non-malignant hematologic disorders, including patients with hemophilia and other inherited or acquired bleeding and thrombotic disorders; patients with acquired bone marrow failure disorders, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria; patients with abnormalities of heme, globin and iron metabolism, including porphyria, hemoglobinopathies, thalassemia and hemochromatosis; patients with both immune and non-immune hemolytic anemia, immune thrombocytopenic purpura, immune neutropenia; and patients with polycythemia, thrombocytosis and leukocytosis.
Our faculty members consult on the inpatient service at the University of Utah and the Huntsman Cancer Hospital for both primary hematologic disorders, such as acute thrombotic thrombocytopenic purpura and complications of sickle cell disease, and secondary hematologic manifestations of medical and surgical disorders such as anemia, heparin induced thrombocytopenia and anti-phospholipid syndrome.
In addition to supporting the medical, surgical and obstetrics and gynecology services, the benign hematology team compliments the multidisciplinary approach to the cancer wellness center, with transfusion medicine support, prevention and treatment of both cancer associated deep venous thrombosis, and cytopenias secondary to cancer chemotherapy.
Blood & Marrow Transplant Program
Bone marrow/blood stem cell transplant is a procedure to replace blood-forming stem cells.
Stem cell transplant is a procedure to replace cells that produce blood. The patient receives high doses of chemotherapy, radiation, or both, to kill cancer cells and healthy cells in the bone marrow where blood is formed. The patient then receives new blood-forming stem cells through an IV. Healthy blood cells develop from the transplanted stem cells.
A stem cell transplant gives a patient healthy blood stem cells collected from the patient or a donor. The stem cells may be collected from blood or from bone marrow. The transplant replaces cancer cells in the patient’s bone marrow.
For more information, or to learn about resources, clinical trials and patient stories, please visit HCI's Blood & Marrow Transplant website.
Hematologic Cancers Program
The Hematologic Cancers Program provides comprehensive, compassionate, state-of-the-art care for people with cancers of the:
- Bone marrow
- Lymph nodes
- Lymphoma & leukemia
For more information, or to learn about resources and patient stories, please visit HCI's Hematologic Cancers Program website.
Acute Myeloid Leukemia Program
Leukemia is a type of cancer in which the bone marrow makes too many of a type of blood cell or abnormal blood cells. In acute myeloid leukemia (AML), the bone marrow produces abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Acute leukemia can get worse quickly if not treated.
For more information, or to learn about resources, clinical trials and patient stories, please visit HCI's Acute Myeloid Leukemia Program website.
Hodgkin Lymphoma Program
Hodgkin lymphoma is a disease where cancer cells form in the lymph system. There are two types of adult Hodgkin lymphoma: classical and nodular lymphocyte-predominant. Another type of lymphoma is called non-Hodgkin lymphoma.
For more information, or to learn about resources and patient stories, please visit HCI's Hodgkin Lymphoma Program website.
Multiple Myeloma Program
Plasma cell neoplasms are diseases where the body makes too many plasma cells. These diseases include monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, and multiple myeloma.
For more information, or to learn about resources, clinical trials and patient stories, please visit HCI's Multiple Myeloma Program website.